San Mateo, CA – According to filings with the U.S. Securities and Exchange Commission, Nocimed is raising $2,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Brett Lanuti played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nocimed
Nocimed harnesses the existing power of Magnetic Resonance Spectroscopy (MRS) for non-invasive, objective quantification of relative chemical differences in tissues applied to assess the relative chemical biomarkers for tissue degeneration and pain. Our focus is to compare relative differences in these degenerative pain biomarkers between lumbar discs in patients receiving MRS exams of those tissues. Nocimed was founded on the premise that when it comes to low back pain diagnosis and related patient management, there has to be a better way. Founded in 2008 by co-inventors Dr. Jeff Lotz and Dr. David Bradford (both world renowned leaders in spine treatment and research from UCSF) and Jim Peacock, Nocimed was created to provide disruptive platform to help significantly improve pain diagnosis, initially focused on spine, using technologies originally invented at and exclusively licensed from UCSF. Nocimed is quickly expanding to bring the non-invasive, pain-free, objectively quantitative lumbar pain diagnostic aid to more people.

To learn more about Nocimed, visit http://nocimed.com/

Contact:
Brett Lanuti, President and Chief Executive Officer
650-241-1740
https://www.linkedin.com/in/brett-lanuti-58138611/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved